Loading clinical trials...
Loading clinical trials...
A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost
Conditions
Interventions
PF-03187207 and Latanoprost Vehicle
Latanoprost 0.005% and PF-03187207 Vehicle
Locations
19
United States
Pfizer Investigational Site
Artesia, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Petaluma, California, United States
Pfizer Investigational Site
Poway, California, United States
Pfizer Investigational Site
Danbury, Connecticut, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Start Date
March 1, 2007
Primary Completion Date
February 1, 2008
Completion Date
July 1, 2008
Last Updated
September 14, 2020
NCT07390890
NCT05902871
NCT07218796
NCT07119580
NCT07076303
NCT06865144
Lead Sponsor
Bausch & Lomb Incorporated
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions